Joint Venture24 Feb 2026, 10:38 am
Shilpa Medicare's Subsidiary, Shilpa Biologicals, Enters Licensing Agreement with SteinCares for Biosimilar Commercialization in Latin America
AI Summary
Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Ltd, and SteinCares, Costa Rica, have entered into a licensing agreement. This agreement grants SteinCares exclusive rights to register, commercialize, and distribute a biosimilar across Latin America. Shilpa Biologicals will complete product development and provide long-term commercial manufacturing from its facility in Dharwad, India. This partnership aims to expand patient access to cost-effective treatments and reinforces SteinCares’ leadership in biosimilars across Latin America.
Key Highlights
- Shilpa Biologicals and SteinCares enter into a licensing agreement for biosimilar commercialization in Latin America.
- SteinCares will hold exclusive rights to register, commercialize, and distribute the biosimilar across Latin America.
- Shilpa Biologicals will complete product development and provide long-term commercial manufacturing from its facility in Dharwad, India.
- Partnership aims to expand patient access to cost-effective treatments and reinforce SteinCares’ leadership in biosimilars across Latin America.
- First product from this strategic partnership and Shilpa Biologicals' entry into the Latin American market.